Results 91 to 100 of about 14,094 (223)

BODY‐Q‐7D Measures Consensus‐Based Patient‐Reported Outcomes for the Management of Obesity Treatment

Obesity, EarlyView.
ABSTRACT Objective A global multidisciplinary consensus initiative identified eight patient‐reported outcome domains important in obesity care: self‐esteem; physical, mental, and social health; eating; stigma; body image; and excess skin. Several of these domains are not represented in generic preference‐based measures typically used in weight loss ...
Anne F. Klassen, Charlene Rae, Claire E. E. de Vries, Farmina Dalaei, Manraj N. Kaur, Lucas Gallo, Maarten Hoogbergen, Lotte Poulsen, Andrea L. Pusic, Stefan J. Cano   +9 more
wiley   +1 more source

Complementary neuroprotective effects of semaglutide and papaya in diabetic encephalopathy via antioxidant and insulin-signaling pathways

Scientific Reports
Diabetic encephalopathy is a chronic neurodegenerative complication of diabetes mellitus characterized by cognitive decline, neuroinflammation, oxidative stress, and impaired insulin signaling. Semaglutide, a glucagon-like peptide-1 receptor agonist, has
Mohamed M. Zeweil, Mai M. Ali, Marium M. Shamaa, Faten I. Mohammed, Marwa Kamal, Mohamed Samir Ahmed Zaki, Afaf Alharthi, Amera A. Ahmed, Amr Elkelish, Mohamed S. Abdel-Maksoud, Komla Mawunyo Dossouvi, Asmaa F. Khafaga   +11 more
doaj   +1 more source

Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case‐Based Evidence

Obesity, EarlyView.
ABSTRACT Objective Glucagon‐like peptide‐1 receptor agonists are increasingly prescribed for obesity. Although generally considered safe, marked appetite suppression and persistent gastrointestinal adverse effects may increase the risk of nutritional deficiencies.
Janice Bidesie, Erik Oudman
wiley   +1 more source

Trends in Diagnosing Obesity: The CALOR Study

Obesity, EarlyView.
Data from the CALOR study suggest that in people with elevated BMI in the US and Japan, there is underdiagnosis of obesity and a high prevalence of diseases interrelated to obesity. ABSTRACT Objective This study aimed to describe characteristics of people with elevated BMI by presence versus absence of obesity diagnosis and trends over time.
Deborah B. Horn, Eva Lesén, Christen M. Gray, Magnus Bjursell, Hironori Waki   +4 more
wiley   +1 more source

Monogenic and syndromic obesity in children: Clinical recognition, genetics, and precision management

Pediatric Investigation, EarlyView.
Monogenic and syndromic obesity in children often arises from defects in the leptin–melanocortin pathway. Understanding these rare genetic causes not only clarifies mechanisms of appetite regulation but also enables precision therapies, offering hope beyond lifestyle interventions.
Hadel Khalil, Eugene Feigin, Hussein Zaitoon   +2 more
wiley   +1 more source

When Fat Goes Astray: Your Liver and Pancreas Get Into Trouble

Portal Hypertension &Cirrhosis, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) and intrapancreatic fat deposition (IPFD) are both common manifestations of ectopic fat accumulation. Although they share multiple risk factors, they also show notable differences in pathological features, standardization of diagnosis, and research maturity.
Yuying Chen, Li Ding, Shan Zhao, Weihong Wang, Jing Zhong, Qiang Yan   +5 more
wiley   +1 more source

A Qualitative Analysis of Patient Experiences Using Semaglutide 2.4 mg for Weight Loss

Obesity Science & Practice
Introduction Semaglutide 2.4 mg (Wegovy) is the first second‐generation anti‐obesity medication approved by the FDA for long‐term obesity treatment. Given the effectiveness of semaglutide 2.4 mg compared to first‐generation anti‐obesity medications and ...
Eion Plenn, Dylan Amin, Jonathan Henry, Gabrielle Leavitt, Jason Walker, Taraneh Soleymani   +5 more
doaj   +1 more source

From cytokine storm to renal scarring in diabetic kidney disease: Biomarkers, risk stratification, and precision therapeutics

Precision Medical Sciences, EarlyView.
Hyperglycemia‐driven cytokine activation initiates a sustained inflammatory cascade in diabetic kidney disease, promoting cellular injury and fibrogenic signaling. Integrating cytokine‐based biomarkers with risk stratification enables precision therapeutics that target inflammation and fibrosis, ultimately aiming to halt progression from early renal ...
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

Glucagon‐like peptide‐1 receptor agonist use and violent crime among US adults

Criminology, EarlyView.
Abstract Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), a class of medications widely prescribed for diabetes and obesity, have exhibited emerging effects on substance use, reward processing, and impulse control. This study examines whether current GLP‐1 RA use moderates established behavioral pathways to violent crime from impulsivity and ...
Daniel C. Semenza, Christopher Thomas
wiley   +1 more source

Use of Glucagon‐Like Peptide 1 Receptor Agonists and the Associated Risk of Hospitalisation in Bipolar Disorder, From a Nationwide Cohort, 2009–2024

Acta Psychiatrica Scandinavica, EarlyView.
ABSTRACT Introduction Diabetes, obesity and bipolar disorder often co‐occur and may have shared pathophysiology. Glucagon‐like peptide 1 receptor agonists (GLP‐1RA) treat diabetes and obesity but their impact on bipolar disorder is unknown. In this era of stagnated pharmacotherapy, we examined psychiatric hospitalisation and absence from work due to ...
Heidi Taipale, Mark Taylor, Markku Lähteenvuo, Ellenor Mittendorfer‐Rutz, Antti Tanskanen, Jari Tiihonen   +5 more
wiley   +1 more source